Strategic partnerships

The imiwn sTLR2 Rapid test is UKCA certified in Great Britain and available elsewhere for research use only. To discuss licensing opportunities for our panel of monoclonal and polyclonal antibodies for research and commercial use, or distribution of our antibodies, reagents and diagnostics, please contact us.

UK Patent Application GB2502531.3.

sTLR2 Rapid pipeline

A whole blood rapid test for point-of-care use will be launched Q2/3, 2025, that will enable the detection of sTLR2 levels in the emergency room and in the intensive care ward in minutes. The company has also identified novel approaches to the detection of sTLR2 and further research is ongoing into potential new applications.